Charles Schwab
GTBP icon

Charles Schwab’s GT Biopharma GTBP Stock Holding History

Charles Schwab’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-862
Closed -$78K – 3527
2022
Q2 		$78K Sell
862
-412
-32% -$31.2K ﹤0.01% 3313
2022
Q1 		$111K Sell
1,274
-248
-16% -$21.9K ﹤0.01% 3396
2021
Q4 		$140K Hold
1,522
– – ﹤0.01% 3407
2021
Q3 		$308K Sell
1,522
-411
-21% -$124K ﹤0.01% 3264
2021
Q2 		$899K Buy
+1,933
New +$803K ﹤0.01% 2971

Other funds holding GTBP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $8.13B AUM 26.03% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Charles Schwab's GTBP Position: Q3 2022 in Review

Charles Schwab sold out of GT Biopharma (GTBP) in Q3 2022, closing a stake of 862 shares — an estimated $78K sold.

Charles Schwab first reported a position in GTBP in Q2 2021 and held it in 5 quarters. The position peaked at $899K in Q2 2021. 34 funds tracked by Wall St. Rank hold GTBP as of Q3 2022.

  • Charles Schwab reported no remaining GT Biopharma position as of Q3 2022 after selling out during the quarter.
  • Charles Schwab sold 862 GT Biopharma shares in Q3 2022, an estimated $78K.
  • Charles Schwab first reported a position in GT Biopharma in Q2 2021 and held it in 5 quarters.
  • Charles Schwab's GT Biopharma position peaked at $899K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2022.

Based on Charles Schwab's 13F filing for Q3 2022, filed 14 Nov 2022.